Theravance Biopharma
TBPH
TBPH
132 hedge funds and large institutions have $399M invested in Theravance Biopharma in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 46 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
7% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 46
2.75% less ownership
Funds ownership: 99.61% → 96.86% (-2.7%)
7% less capital invested
Capital invested by funds: $431M → $399M (-$31.1M)
Holders
132
Holding in Top 10
4
Calls
$118K
Puts
$38K
Top Buyers
| 1 | +$12.7M | |
| 2 | +$4.6M | |
| 3 | +$4.08M | |
| 4 |
JP Morgan Chase
New York
|
+$1.94M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.73M |
Top Sellers
| 1 | -$20.3M | |
| 2 | -$9.88M | |
| 3 | -$5.8M | |
| 4 |
BlackRock
New York
|
-$3.63M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$933K |